2026-05-29T20:52:13Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/146312026-02-03T11:33:28Zcom_10630_2254col_10630_37953

00925njm 22002777a 4500 dc García-Vilas, Javier A. author Pino-Ángeles, Almudena author Martínez-Póveda, Beatriz Amparo author Rodríguez-Quesada, Ana María author Medina-Torres, Miguel Ángel author 2017-01 The natural bioactive compound damnacanthal inhibits several tyrosine kinases. Herein, we show that -in fact- damancanthal is a multi kinase inhibitor. A docking and molecular dynamics simulation approach allows getting further insight on the inhibitory effect of damnacanthal on three different kinases: vascular endothelial growth factor receptor-2, c-Met and focal adhesion kinase. Several of the kinases targeted and inhibited by damnacanthal are involved in angiogenesis. Ex vivo and in vivo experiments clearly demonstrate that, indeed, damnacanthal is a very potent inhibitor of angiogenesis. A number of in vitro assays contribute to determine the specific effects of damnacanthal on each of the steps of the angiogenic process, including inhibition of tubulogenesis, endothelial cell proliferation, survival, migration and production of extracellular matrix remodeling enzyme. Taken altogether, these results suggest that damancanthal could have potential interest for the treatment of cancer and other angiogenesisdependent diseases. Cancer Letters 358 (2017) 1-11 http://hdl.handle.net/10630/14631 Cancer The noni anthraquinone damnacanthal is a multi-kinase inhibitor with potent anti-angiogenic effects